× You have changed the size of your browser. Reload the page for best representation and functionality.
Reload
× For horizontal scrolling please use the arrows.
OK
Print table
The recently announced acquisition of Bioverativ and on-going offer to acquire Ablynx are included in the current consensus estimates.
Last update on 29/03/2018
Business P&L (in EURm except otherwise stated)Q1 2017FY 2017Q1 2018EFY 2018EFY 2019EFY 2020EFY 2021E
Net sales
- Number of Estimates   12 12 12 12 
- Highest     35,959 38,305 40,472 42,296 
- Consensus 8,648 35,055 34,884 36,516 38,315 40,038 
- Lowest     33,783 35,570 37,189 37,717 
Other revenues
- Number of Estimates   12 12 12 12 
- Highest     1,256 1,435 1,515 1,530 
- Consensus 249 1,149 1,171 1,210 1,254 1,284 
- Lowest     1,025 950 1,045 1,045 
Cost of sales
- Number of Estimates   12 12 12 12 
- Highest     -11,042 -11,398 -11,529 -11,878 
- Consensus -2,697 -11,445 -11,405 -11,802 -12,230 -12,657 
- Lowest     -11,831 -12,522 -13,156 -13,561 
Gross Profit
- Number of Estimates   12 12 12 12 
- Highest     25,427 27,038 29,047 30,130 
- Consensus 6,200 24,759 24,651 25,924 27,339 28,666 
- Lowest     23,958 25,200 26,718 26,845 
Gross margin as % of net sales
- Number of Estimates   12 12 12 12 
- Highest     71.1 72.1 72.9 73.2 
- Consensus 71.7 70.6 70.7 71.0 71.4 71.6 
- Lowest     70.1 69.9 70.3 70.6 
R&D expenses
- Number of Estimates   12 12 12 12 
- Highest     -5,422 -5,604 -5,606 -5,668 
- Consensus -1,309 -5,472 -5,643 -5,918 -6,097 -6,265 
- Lowest     -5,860 -6,088 -6,325 -6,600 
SG&A expenses
- Number of Estimates   12 12 12 12 
- Highest     -9,741 -9,864 -9,910 -10,000 
- Consensus -2,478 -10,058 -10,069 -10,341 -10,632 -10,903 
- Lowest     -10,469 -10,939 -11,395 -11,730 
Other current operating income/expense
- Number of Estimates   11 11 11 11 
- Highest     261 77 -5 -5 
- Consensus 34 -76 -287 -588 -929 
- Lowest     -282 -666 -1,136 -1,706 
Share of profit/loss of associates
- Number of Estimates   11 11 11 11 
- Highest     372 544 489 550 
- Consensus 30 235 288 350 385 452 
- Lowest     227 275 266 287 
Net income attributable to non-controlling interests
- Number of Estimates   10 10 10 10 
- Highest     -83 -4 -4 -4 
- Consensus -35 -125 -114 -88 -81 -77 
- Lowest     -150 -135 -142 -150 
Business operating income
- Number of Estimates   12 12 12 12 
- Highest     9,323 10,083 11,102 11,943 
- Consensus 2,442 9,343 9,033 9,659 10,330 10,942 
- Lowest     8,537 9,131 9,644 9,662 
Operating margin as % of net sales
- Number of Estimates   12 12 12 12 
- Highest     26.5 27.7 28.6 29.2 
- Consensus 28.2 26.7 25.9 26.5 27.0 27.3 
- Lowest     25.3 25.5 25.6 25.6 
Financial income & expense
- Number of Estimates   12 12 12 12 
- Highest     -124 -168 -140 -90 
- Consensus -63 -273 -319 -308 -283 -259 
- Lowest     -390 -448 -437 -443 
Tax rate in %
- Number of Estimates   11 11 11 11 
- Highest     -21.5 -21.5 -21.6 -21.6 
- Consensus -24.5 -23.5 -22.1 -22.1 -22.1 -22.1 
- Lowest     -22.6 -23.3 -23.1 -23.0 
Business net income
- Number of Estimates   12 12 12 12 
- Highest     7,104 7,748 8,587 9,048 
- Consensus 1,795 6,964 6,826 7,342 7,892 8,400 
- Lowest     6,608 7,052 7,382 7,313 
Net profit margin as % of net sales
- Number of Estimates   12 12 12 12 
- Highest     20.0 20.9 21.6 22.3 
- Consensus 20.8 19.9 19.6 20.1 20.6 21.0 
- Lowest     19.1 19.5 19.6 19.4 
Number of shares
- Number of Estimates   11 11 11 11 
- Highest     1,270 1,256 1,252 1,249 
- Consensus 1,262 1,257 1,249 1,241 1,231 1,221 
- Lowest     1,235 1,228 1,211 1,192 
Business EPS (in EUR)
- Number of Estimates   12 12 12 12 
- Highest     5.74 6.32 7.08 7.34 
- Consensus 1.42 5.54 5.48 5.92 6.42 6.88 
- Lowest     5.27 5.61 6.02 6.13 
Dividend per Share (in EUR)
- Number of Estimates   
- Highest     3.10 3.35 3.60 3.90 
- Consensus 3.03 3.01 3.16 3.35 3.51 
- Lowest     2.82 3.03 3.12 3.22 
More estimates on Vara Online Services
Last update on 29/03/2018
The above consensus estimates are reset after each quarterly report. Hence, the estimates do not contain any estimates older than three months.
Disclaimer
This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.